Efficacy News and Research

RSS
New light on many biological differences between individual breast cancers

New light on many biological differences between individual breast cancers

Potential breast cancer patients for new immune-targeting therapies

Potential breast cancer patients for new immune-targeting therapies

Generon commences F-627 Phase II trial in breast cancer

Generon commences F-627 Phase II trial in breast cancer

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

Abbott to purchase AP214 hormone analogue from Action Pharma

Abbott to purchase AP214 hormone analogue from Action Pharma

Clinical trial to investigate statins in patients with acute severe respiratory failure

Clinical trial to investigate statins in patients with acute severe respiratory failure

UCLA creates crowd-sourced online gaming system to detect malaria

UCLA creates crowd-sourced online gaming system to detect malaria

Emergent BioSolutions first quarter total revenues increase to $50.3M

Emergent BioSolutions first quarter total revenues increase to $50.3M

Nanoparticle carriers successfully deliver therapeutic doses of cancer drug

Nanoparticle carriers successfully deliver therapeutic doses of cancer drug

Large-scale, patient-specific simulations of blood function

Large-scale, patient-specific simulations of blood function

New pressure-technology device effective in reducing incidence of PONV

New pressure-technology device effective in reducing incidence of PONV

Combination of two mTOR inhibitors stops growth of hepatocellular carcinoma

Combination of two mTOR inhibitors stops growth of hepatocellular carcinoma

Novel stem cell transplantation holds promise for HIV prevention

Novel stem cell transplantation holds promise for HIV prevention

Europe becoming 'hotspot' for emerging infections, study suggests

Europe becoming 'hotspot' for emerging infections, study suggests

SC formulation of Genentech’s ACTEMRA shows promise against RA

SC formulation of Genentech’s ACTEMRA shows promise against RA

CSI third quarter revenues increase 5% to $21.2 million

CSI third quarter revenues increase 5% to $21.2 million

Biosynthetic polyphenol improves cognitive function in mice with AD

Biosynthetic polyphenol improves cognitive function in mice with AD

XenoPort first quarter revenues increase to $10.4 million

XenoPort first quarter revenues increase to $10.4 million

EKOS launches two landmark clinical studies on pulmonary embolism

EKOS launches two landmark clinical studies on pulmonary embolism

FDA approval of TDF/FTC as PrEP for HIV infection receives support

FDA approval of TDF/FTC as PrEP for HIV infection receives support

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.